Pfizer's Prevnar and Sanofi's ActHIB cleared for Japanese market

After nearly three weeks of suspended vaccinations, Japan has cleared the path for Sanofi-Aventis' ActHIB and Pfizer's Prevnar--marketed as Prevenar--to return to the Japanese market as soon as April 1. The vaccines, ActHIB for hemophilius influenza and meningitis and pneumonia preventative Prevnar, were originally called off the market after five children between the ages of six months and two years died after receiving one or both of the vaccines. Soon after, the Japanese health ministry cleared the vaccines of any connection to the deaths, but the embargo remained in place.

Both companies released statements noting that the Ministry of Health, Labour, and Welfare's Safety Measures Investigation Committee and Post-Vaccination Adverse Event Study panel reaffirmed the vaccines' innocence in the children's deaths.

- see the WSJ piece
- read Bloomberg's coverage

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.